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Abstract
Background: Confirming tuberculosis (TB) disease in suspects in resource limited settings is challenging and calls
for the development of more suitable diagnostic tools. Different Mycobacterium tuberculosis (M.tb) infection phase-
dependent antigens may be differentially recognized in infected and diseased individuals and therefore useful as
diagnostic tools for differentiating between M.tb infection states. In this study, we assessed the diagnostic potential
of 118 different M.tb infection phase-dependent antigens in TB patients and household contacts (HHCs) in a high-
burden setting.
Methods: Antigens were evaluated using the 7-day whole blood culture technique in 23 pulmonary TB patients
and in 19 to 21 HHCs (total n = 101), who were recruited from a high-TB incidence community in Cape Town,
South Africa. Interferon-gamma (IFN-g) levels in culture supernatants were determined by ELISA.
Results: Eight classical TB vaccine candidate antigens, 51 DosR regulon encoded antigens, 23 TB reactivation
antigens, 5 TB resuscitation promoting factors (rpfs), 6 starvation and 24 other stress response-associated TB
antigens were evaluated in the study. The most promising antigens for ascertaining active TB were the rpfs
(Rv0867c, Rv2389c, Rv2450c, Rv1009 and Rv1884c), with Areas under the receiver operating characteristics curves
(AUCs) between 0.72 and 0.80. A combination of M.tb specific ESAT-6/CFP-10 fusion protein, Rv2624c and Rv0867c
accurately predicted 73% of the TB patients and 80% of the non-TB cases after cross validation.
Conclusions: IFN-g responses to TB rpfs show promise as TB diagnostic candidates and should be evaluated
further for discrimination between M.tb infection states.
Background
The diagnosis of tuberculosis (TB) disease remains a
challenge in resource-limited settings. This is particu-
larly due to limitations in sputum smear microscopy [1],
the cheapest and widely used test in such settings. Sev-
eral attempts have been made towards the development
of better diagnostic tests for TB [1]. The most signifi-
cant development in the field has been the introduction
of the automated real-time sputum processing molecular
beacon assay, XpertMTB/RIF assay (Cepheid Inc., CA,
USA) [2] into clinical practice but the relatively high
operating costs preclude its use in resource-poor set-
tings which often suffer from the highest TB burdens
[3]. Furthermore, the dependence of most of these tests
on sputum implies that they are not suitable for patients
with difficulties in providing good quality sputum sam-
ples such as children, extrapulmonary TB cases, or in
cases where the sputum itself is negative (for example,
many patients with HIV-Mycobacterium tuberculosis (M.
tb) co-infections). Immunodiagnostic assays might hold
promise in such cases [4] especially if they can be devel-
oped into point-of-care tests.
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of immunodiagnostic tools for M.tb has been the advent
of the interferon gamma release assays (IGRAs). Com-
mercially available IGRAs include the ELISA-based
Quantiferon TB Gold assays (Cellestis, Victoria, Austra-
lia) and the ELISPOT-based T SPOT.TB test (Oxford
Immunotec, Abington, UK). Notwithstanding the proven
usefulness of these assays in the diagnosis of M.tb infec-
tion, especially in comparison to the tuberculin skin test
(TST) [5-7], an important limitation of the tests is that
they do not discriminate between latent M.tb infection
(LTBI) and active TB disease. This implies limited utility
in high-burden settings where the prevalence of LTBI is
usually high. In order to develop T cell-based assays for
the diagnosis of active TB, it is imperative to identify
new host markers expressed in response to established
M.tb-dependent antigens, such as those used in IGRAs
(ESAT-6, CFP-10, TB7.7), or novel M.tb antigens
uniquely recognized by patients with active TB or LTBI.
In response to the continued pressure mounted by
host immune responses in the course of M.tb infection,
the bacterium is believed to respond by self-regulating
the expression of many genes [8,9]. Using in vivo and in
vitro models believed to mimic the conditions encoun-
tered within the host by the tubercle bacillus as infec-
tion progresses from latency to active disease,
investigators have been able to identify infection phase-
dependent genes with diagnostic potential [10,11]. In
the present study, we assessed the potential diagnostic
utilities of 118 M.tb infection phase-dependent antigens
in TB patients and household contacts (HHCs) in a
high-TB burden population. As part of a large ongoing
TB biomarker study, we investigated the antigens in a 7-
day diluted whole blood assay for their diagnostic poten-
tial for active TB.
Methods
Study subjects
Participants were recruited from the Ravensmead/Uitsig
community in Cape Town, South Africa, as part of an
ongoing Bill and Melinda Gates Foundation funded
Grand Challenges in Global Health (GC6-74) study
(http://www.biomarkers-for-tb.net/). Participants
included in this study were enrolled between October
2006 and April 2007. All TB patients were self-report-
ing, untreated cases with a first episode of TB and were
acid fast bacilli (AFB) positive on two sputum smears.
HHCs had been living in the same house as an adult TB
case who was diagnosed not more than 2 months before
recruitment of the contact. All HHCs had antero-poster-
ior view chest X-rays and assisted sputum samples
taken. The X-rays were all evaluated as normal and the
sputum samples found negative for AFB. Demographic
data was collected on all participants and a clinical
questionnaire completed. All participants tested negative
with an HIV rapid test (Abbot Determine™ HIV 1/2;
Abbott, Wiesbaden, Germany). Inclusion criteria for all
participants were: age between 18 and 60 years, willing-
ness to undergo HIV testing and to give written
informed consent for participation in the study. Exclu-
sion criteria for all participants included HIV infection,
previous or current TB treatment, participation in a
drug or vaccine trial at or within the 6 months preced-
ing recruitment, other chronic illnesses and pregnancy.
At enrolment, 10 ml of heparinized blood was collected
from all participants and transported within 2 h of col-
lection to the laboratory where a 7-day whole blood
assay (WBA) (described below) was performed. Ethical
approval for the study was obtained from the Commit-
tee for Human Research of the University of
Stellenbosch.
Antigens
A total of 118 M.tb infection phase-dependent antigens
(112 recombinant proteins and 8 peptide pools) were
evaluated in the study. Eight of these antigens (ESAT-6/
CFP-10 fusion protein (ESAT-6/CFP-10fp), TB10.4
(Rv0288), TB10.3 (Rv3019c), TB7.7 (Rv2654c), Ag85A
(Rv3804c), Ag85B (Rv1886c), HSP65 (Rv0440), ESAT-6
(Rv3875)), were well-characterized TB antigens and
were evaluated as “control antigens”. Fifty-one antigens
were DosR-induced antigens, 23 were reactivation anti-
gens, 5 were rpfs, 6 were starvation antigens (other than
Rv2654c) and the other 24 are known to be associated
with stress conditions (Additional file 1: Tables S1,
Additional file 2: Table S2, Additional file 3: Table S3,
Additional file 4: Table S4, Additional file 5: Table S5,
Additional file 6: Table S6). One of the peptide pools
(Rv2659) was evaluated in three separate pools (pools
A-C) while Ag85A and Ag85B were evaluated together
in culture. With the exception of ESAT-6 and Rv3407,
all the recombinant proteins were produced at Leiden
University Medical Center (LUMC), The Netherlands.
Recombinant ESAT-6 and all peptide pools were from
SSI, and Rv3407 from the Max Plank Institute for Infec-
tion Biology (Berlin, Germany).
For the antigens that were available as peptide pools,
there were 6 to 13 peptides in each pool. Each of the
peptides was 15 amino acids long. There were eight
amino acid overlaps between the peptides in each pool
(Additional file 7: Table S7).
Recombinant antigens were produced as previously
described [12]. Briefly, M.tb genes were amplified by
PCR from genomic DNA of M.tb a n dc l o n e du s i n gt h e
Gateway technology platform (Invitrogen, Carlsbad, CA)
with pDEST17 expression vector containing an N-term-
inal histidine tag (Invitrogen). Sequencing was per-
formed on selected clones to confirm identity of all
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expressed in E. coli BL21(DE3) and purified as described
to remove any traces of endotoxin. Each purified recom-
binant protein was analyzed by 12% SDS-PAGE followed
by Coomassie Brilliant Blue staining and Western-blot-
ting with an anti-His antibody (Invitrogen) to confirm
size and purity. Endotoxin contents were below 50 IU/
mg recombinant protein as tested using a Limulus Ame-
bocyte Lysate (LAL) assay (Cambrex, East Rutherford,
NJ), and less than 0.1 IU/mg in some cases. Recombi-
nant proteins were tested to exclude protein non-speci-
fic T cell stimulation and cellular toxicity in IFN-g
release assays using PBMC of in vitro PPD-negative,
healthy Dutch donors recruited at the Blood bank San-
quin, Leiden, The Netherlands. None of these controls
had experienced any known prior contact with TB
patients.
Whole blood assay
Antigens were evaluated at a final concentration of 10
μg/ml as previously described [13]. Briefly, antigens
were reconstituted as instructed by the respective manu-
facturers, to a concentration of 20 μg/ml, after which
they were aliquoted into 96-well U-bottom plates (100
μl per well) in triplicates. Antigen plates were then fro-
z e na t- 8 0 ° Cu n t i lt h ed a yo fW B A .O nt h ed a yo f
WBA, antigen plates were thawed and 100 μlo f1i n5
diluted whole blood [dilutedw i t hp r e - w a r m e d( 3 7 ° C )
medium (RPMI 1640 containing L-glutamine) (Sigma)],
was added to the antigen and control wells. Plates were
then incubated until day 7 in a humidified, 5% CO2,3 7 °
Ci n c u b a t o r .1 5 0μl of supernatant was harvested from
each of the three antigen/control wells, pooled in a
micro centrifuge tube (total of 450 μl per antigen per
study participant), divided into 3 aliquots and frozen at
-80°C until further use. The unstimulated control wells
received medium without antigen while the positive
control wells received phytohaemagglutinin (PHA)
(Sigma) at 0.5 μg/ml.
IFN-g ELISA
ELISAs were performed using a pair of monoclonal anti-
bodies from BD Pharmingen™, (BD Biosciences).
Briefly, 96-well flat-bottomed micro-titre plates (Nunc)
were coated with 2 μg/ml (50 μl) of the purified mouse
anti-human IFN-g monoclonal capture antibody (diluted
in 0.1 M NaHCO3). After overnight incubation at 4°C,
plates were washed and blocked with 10% heat-inacti-
vated fetal calf serum (150 μl) in phosphate buffered sal-
ine for 2 h (room temperature). After another wash,
serial dilutions of recombinant human IFN-g standard
(BD Pharmingen™), and the samples (100 μl per well),
were added to the designated wells, and plates incubated
o v e r n i g h ta t4 ° C .P l a t e sw e r et h e nw a s h e da n d1μg/ml
(100 μl) of the biotinylated mouse-anti-human IFN-g
detection antibody (BD Pharmingen™) added. After 1 h
incubation (room temperature) and a further wash, 2.5
μg/ml (100 μl) of streptavidin peroxidase (Sigma) was
added to all wells, followed by addition of the substrate
(O-phenylene diamine-dihydrochloride [Sigma]) (200 μl/
well). Plates were then incubated in the dark for 25
mins and the optical densities read at 450 nm. All sam-
ples, standards and controls were assayed in duplicate.
IFN-g concentrations were calculated from a four-para-
meter logistic curve using the microplate manager soft-
ware (Bio Rad Laboratories). A PHA-stimulated internal
positive control supernatant (evaluated on all plates to
assess the variability of the ELISA assay) had an average
interplate coefficient of variation of 3.6% (95% confi-
dence interval, 2.7-4.6%).
Although the ELISA used in our study has been used
in other published studies [13-15], the standard curve
for the assay ranged from 31-4000 pg/ml and many of
the responses elicited by the antigens we have tested fell
below the lowest point on the curve. To verify our
observations, we re-evaluated the supernatants from
promising antigens by a commercially available IFN-g
ELISA kit (Quantiferon TB Gold (QFT) ELISA, Cellestis,
Australia). According to the manufacturer, the detection
limit of the QFT ELISA is 0.05 IU/ml (about 2 pg/ml).
The validation ELISA (QFT ELISA) was performed
according to the manufacturer’s instructions.
Statistical analysis
IFN-g responses obtained with the Quantiferon ELISA
(in IU/ml) were converted to pg/ml by multiplying by
40 [16]. Differences in IFN-g levels elicited by the anti-
gens were evaluated by the Mann Whitney U test for
nonparametric data analysis. Optimal cut-off levels for
differentiating between TB disease and no TB were
ascertained by receiver operating characteristics (ROC)
analysis using the “R” statistical programming language.
The predictive abilities of combinations of antigens to
differentiate between TB disease and no TB was investi-
gated by performing best subsets general discriminant
analysis (GDA), with leave-one-out cross validation as
described previously [17]. A 5% significance level was
used as guideline for determining significant associa-
tions. The data were analyzed using the Statistica 8 soft-
ware, (Statsoft, Ohio, USA) and GraphPad prism,
version 5.00 for Windows (GraphPad Software, San
Diego, California, USA).
Results
A total of 124 participants, 23 TB patients and 101
HHCs were enrolled in the study. The mean (± standard
deviation) age of participants was 31.7 (± 15.3) years and
76 (61.3%) were female. Although neither IGRA nor
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from our previous studies that 78-89% of adult HIV-
negative TB HHCs from the study community are TST
positive (10 mm cut-off) with a mean TST induration of
about 23 mm [5,13,17]. All the antigens (n = 118) were
evaluated in all TB patients (n = 23) and in groups of
19 to 21 HHCs. Because of the large number of antigens
evaluated in the study, only antigens for which reporta-
ble data was generated are shown in the results section
of the main manuscript. The diagnostic accuracy data
for all the other antigens is shown in Additional file 8:
Table S8 and Additional file 9: Figure S1. The detailed
description of all the antigens evaluated in the study is
shown in Additional file 1: Table S1, Additional file 2:
Table S2, Additional file 3: Table S3, Additional file 4:
Table S4, Additional file 5: Table S5, Additional file 6:
Table S6, Additional file 7: Table S7.
IFN-g responses in assay controls
The median IFN-g concentration detected in the unsti-
mulated control supernatants in both TB patients and
HHCs was 0 pg/ml (range 0.0-4.3 pg/ml in TB patients
and 0.0-585.4 pg/ml in HHCs). There was no significant
difference in the unstimulated IFN-g responses between
the TB patients and HHCs (p = 0.10). The median IFN-
g concentration detected in PHA-stimulated superna-
tants in HHCs (1331.0 pg/ml, range, 0.0 to > 4000 pg/
ml), was significantly higher than that observed in TB
patients (326.6 pg/ml, range, 0.0 to > 4000 pg/ml) (p =
0.01), as previously observed [18]. The IFN-g response
obtained for the unstimulated control for each partici-
pant was subtracted from all antigen/control-stimulated
levels before further analysis of the data.
IFN-g production in response to classical TB antigens
Eight M.tb classical antigens (Additional file 1: Table S1)
were evaluated in this study. TB10.4 and TB7.7 were
available as peptide pools while all other classical anti-
gens were recombinant proteins. Ag85A and Ag85B
were pooled and tested as a single condition.
ESAT-6/CFP-10fp, ESAT-6, TB10.4 and TB10.3 were
the most frequently recognized antigens in TB patients
and HHCs. Recognition of TB7.7, Ag85A and B and
HSP65 was poor in both subject groups (Figure 1).
There were no significant differences in the IFN-g
responses elicited by any of the antigens between the
two study groups (p values all > 0.05, range, 0.06-0.98).
Similarly, when the ability of the antigens to differentiate
between TB patients and HHCs was evaluated using
ROC analysis, the antigen with the highest area under
t h eR O Cc u r v e( A U C )w a sE S A T - 6( A U Co f0 . 6 6 ) .T h e
AUCs for all the classical TB antigens were between
0.44 and 0.66 (Additional file 8: Table S8, Additional file
9: Figure S1).
DosR regulon encoded antigens
Fifty-one DosR regulon encoded antigens (Additional
file 2: Table S2) were evaluated in this study. All anti-
gens were recombinant proteins. These antigens were
more frequently recognized in HHCs, confirming pre-
vious work [13,19-21]. When antigen induced IFN-g
levels were compared between the two subject groups,
the difference in IFN-g responses were significant for 14
of the 51 antigens evaluated, namely: Rv1735c, Rv2006,
Rv2625c, Rv1996, Rv2032, Rv2629, Rv3126c, Rv0081,
Rv2631, Rv3130c, Rv2624c, Rv2007c, Rv2028c and
Rv3134 (Table 1). The p-values for the differences in
IFN-g for six other antigens showed a trend for differen-
tial IFN-g induction (range of p-values, 0.06 - 0.08),
namely: Rv2029c, Rv2030c, Rv3129, Rv2630, Rv3133c
and Rv3127 (Additional file 8: Table S8).
When the data was analyzed by ROC analysis, 8 of the
14 antigens that showed significant differences with the
Mann Whitney U test (Rv2625c, Rv1996, Rv2032,
Rv0081, Rv2624c,Rv2006, Rv2629 and Rv2007c) differen-
tiated between the two groups with AUCs above 0.70
(Table 1, Figure 2). The diagnostic potentials of all the
other DosR encoded antigens evaluated is shown in
Additional file 8: Table S8 and the ROC curves are
shown in (Additional file 9: Figure S1).
TB reactivation antigens
A total of 23 TB reactivation associated antigens (Addi-
tional file 3: Table S3) were evaluated in this study. All
antigens were available as recombinant proteins. Recog-
nition of most of these antigens was poor in both TB
patients and HHCs (data not shown). Two of the most
frequently recognized of these antigens (Rv1131 and
Rv1471) discriminated between the TB cases and HHCs
with p values < 0.05. When the data was assessed by
ROC analysis, however, only Rv1131 discriminated
b e t w e e nt h eT Bc a s e sa n dH H C sw i t ha nA U C≥ 0.70
(Additional file 8: Table S8, Additional file 9: Figure S1).
Resuscitation promoting factors (rpfs)
All of the five known M.tb rpfs (Additional file 4: Table
S4) were evaluated in this study as recombinant pro-
teins. All rpfs elicited significantly higher IFN-g
r e s p o n s e si nH H C s( T a b l e2 )w i t hA U C sr a n g i n gf r o m
0.72 to 0.80 (Figure 3) in discriminating TB from non
TB.
Starvation antigens and other stress induced proteins
Twenty-four other recombinant antigens, most of which
are associated with stress conditions [22] (Additional file
5: Table S5) and 7 starvation induced antigens, all pep-
tide pools (Additional file 6: Table S6), were evaluated
in this study. Recognition of these antigens was poor in
both TB cases and HHCs. There was no significant
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gens between the TB cases and HHCs (range of p-
values, 0.21-0.94). The antigen with the highest AUC for
differentiating between the two groups after ROC analy-
sis was Rv0244 (AUC = 0.61). The data indicating the
diagnostic potential of these and all the other antigens
evaluated in the study is shown in Additional file 8:
Table S8 and the ROC curves are shown in (Additional
file 9: Figure S1).
Ability of combinations of antigens to discriminate
between TB disease and no TB
To investigate whether the discriminative abilities of the
antigens could be enhanced when used in combinations,
IFN-g data obtained for all antigens and controls were
fitted into general discriminant analysis (GDA) models.
Optimal prediction of the presence or absence of active
TB was achieved when antigens were used in combina-
tions of four. The most frequently occurring antigens in
the top 10 four-antigen combinations that best predicted
the presence or absence of TB disease were Rv2032 and
ESAT-6/CFP-10fp (or ESAT-6 alone), appearing in all
10 antigen combinations (Figure 4). Addition of two
other antigens (Rv1733c + Rv1736c(C-terminal part) or
Rv1997c + Rv1733c) to ESAT-6/CFP-10fp and Rv2032
correctly classified 90% of the TB cases and 84% of the
HHCs after leave-one-out cross validation.
Validation of ELISA results with the Quantiferon TB Gold
ELISA kit
The standard curve for the ELISA employed in this
study ranged from 31 pg/ml to 4000 pg/ml. Although
the standard curve was useful at detecting high magni-
tude IFN-g responses, IFN-g responses below 31 pg/ml
could not be reliably estimated. As optimal cut-off
values obtained for the most promising antigens evalu-
ated in this study (after background correction) were as
low as 0.5 pg/ml, we performed validation of the results
with another ELISA (the commercially available QFT
ELISA kit). Supernatants from the best discriminatory
antigens (the top five single DosR antigens (Rv2032c,
Rv2625c, Rv1996, Rv0081, Rv2624c) and the top three
rpfs (Rv0867c, Rv1009 and Rv2389c)) were re-evaluated.
This was done in 15 TB cases and 15 HHCs who were
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Figure 1 IFN-g levels (pg/ml) elicited by classical TB antigens in 23 TB patients (TB) and 20 household contacts (HHC). Responses in TB
cases are indicated by open symbols and those in household contacts by closed symbols. Error bars represent the median. Ag85A/B = Ag85A
and Ag85B tested together, HSP = heat shock protein, PHA = Phytohaemagglutinin.
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control and ESAT-6/CFP-10fp stimulated supernatants
from these 30 subjects were also evaluated.
Of the nine antigens re-evaluated by the QFT ELISA,
significant differences between the TB cases and HHCs
were only obtained for the three rpfs (Table 3). Like-
wise, after ROC analysis, all 3 rpfs discriminated
between the TB cases and HHCs with AUCs > 0.73
(Table 3). When the predictive abilities of antigen com-
binations were evaluated by GDA, the most accurate
antigen model (ESAT-6/CFP-10fp + Rv2624c +
Rv0867c) accurately classified 83% of all study partici-
pants into their respective groups. After leave-one-out
cross validation the prediction accuracy was 73% for TB
cases and 80% for HHCs (Table 4). The most frequently
occurring antigens in the top 10 GDA combinations
were ESAT-6/CFP-10fp, Rv2624c and Rv2032 (Figure 5)
and all the promising antigen combinations included
ESAT-6/CFP-10fp, Rv2624c and one of the three rpfs
(Rv0867c, Rv1009, and Rv2389c) (Table 4).
Discussion
T h ed i a g n o s t i cp o t e n t i a lo f1 1 8M.tb infection phase-
dependent antigens was investigated in this study. Rpfs
were the most discriminatory antigens with
combinations of antigens correctly predicting up to 73%
of the TB cases and up to 80% of HHCs after cross-
validation.
The classical M.tb antigens, evaluated here as ‘control
antigens’, have been extensively studied. Most of these
antigens are strongly recognized with high IFN-g pro-
duction in TB patients or infected individuals [23-28]
and are key components of candidate TB vaccines
[29-39] or form part of antigen cocktails that are used
in diagnostic tests. The frequent recognition of ESAT-6/
CFP-10fp (and ESAT-6 alone) in both TB cases and
HHCs, justifies the use of these antigens in all commer-
cially available IGRAs. Recognition of TB7.7 (used in
the QFT In Tube test, Cellestis, Australia), Ag85A/B
a n dH S P 6 5w a sp o o r .T h i si si na g r e e m e n tw i t he a r l i e r
studies, which suggest that the majority of response to
M.tb infection is largely driven by ESAT-6 and CFP-10,
with TB7.7 providing only a small extra benefit (author’s
unpublished data). When previously evaluated in sero-
diagnostic approaches, Ag 85A and B also performed
poorly [40] while detection of antibodies or antigens to
HSP65 in serum and CSF, respectively, diagnosed active
TB with an accuracy above 80% [41,42]. The poor
recognition of Ag85A and B, TB7.7 and HSP65 as
assessed by IFN-g production in our study group may
Table 1 Abilities of DosR antigens to discriminate between TB disease and no TB.
Antigen TB cases HHCs P-value AUC Cut-off
value
Sensitivity
(%)
Specificity
(%)
Rv1735c 0.0 (0.0-140.9 12.0 (0.0-1049.0) 0.040 0.68 < 6 83 (19/23) 52 (11/21)
Rv2625c 0.0(0.0-1784.0) 17.3(0.0-1121.0) 0.007 0.74 < 6.1 83 (19/23) 70 (14/20)
Rv1996 0.0(0.0-180.6) 5.0(0.0-
314.1)
0.004 0.75 < 0.5 83 (19/23) 76 (16/21)
Rv2032 0.0(0.0-39.2) 17.7(0.0-
331.6)
0.002 0.77 < 0.1 83 (19/23) 70 (14/20)
Rv3126c 0.0(0.0-1173.0) 4.6(0.0-
820.6)
0.030 0.69 < 4.6 87 (20/23) 50 (10/20)
Rv0081 0.0(0.0-53.6) 5.5(0.0-
732.1)
0.020 0.71 < 9.4 96 (22/23) 50 (10/20)
Rv3130c 0.0(0.0-41.9) 0.0(0.0-
67.4)
0.050 68.0 < 1.1 91 (21/23) 45 (9/20)
Rv2624c 0.0(0.0-288.6) 3.4(0.0-
78.7)
0.010 0.73 < 1.0 91 (21/23) 55 (11/20)
Rv2028c 0.0(0.0-174.9) 0.0(0.0-
72.5)
0.030 0.69 < 2.3 96 (22/23) 45 (9/20)
Rv3134c 0.0(0.0-0.0) 0.0(0.0-
51.2)
0.050 0.68 < 4.9 100 (23/23) 35 (7/20)
Rv2006 0.0 (0.0-2738.0) 12.3 (0.0-1030.0) 0.002 0.77 < 1.0 83 (19/23) 80 (16/20)
Rv2629 0.0 (0.0-1720.0) 3.2 (0.0-331.6) 0.020 0.71 < 1.3 91 (21/23) 55 (11/20)
Rv2631 0.0 (0.0-1071) 0.0 (0.0-454.8) 0.030 0.69 < 1.3 96 (22/23) 45 (9/20)
Rv2007c 0.0 (0.0-3456.0) 0.7(0.0-447.9) 0.010 0.73 < 0.1 91 (21/23) 55 (11/20)
Median levels of IFN-g (pg/ml) and ranges (in parenthesis) elicited in patients with active TB and household contacts by the most promising DosR antigens.
Antigens that discriminated between the two groups with P-values < 0.05 are shown. Abilities of the antigens to differentiate between the two study groups are
also shown. Antigens in bold discriminated between TB and no TB with AUC ≥ 0.70 after ROC analysis. AUC = Area under the ROC curve
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Page 6 of 14suggest that the conditionsu n d e rw h i c ht h ea n t i g e n s
were tested was not optimal, or perhaps that the
humoral and cell mediated responses to these antigens
are different. It may also imply that the worth of testing
candidate vaccines based on these antigens needs to be
reassessed in certain populations. However, it has been
shown that responses to TB antigens could be enhanced
if antigens are delivered using vectors such as the
Bordetella pertusis adenylate cyclase vector [43], use of
other adjuvants [32] or the addition of IL-7 [44] and IL-
12 [45] into cultures. It is not known if addition of cyto-
kines might have improved upon the diagnostic ability
of the antigens. Whether some of these antigens would
perform better if used in serological assays [41,42]
requires further investigation. However, the World
Health Organization has recently cautioned against the
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Figure 2 Receiver operating characteristic (ROC) curves showing the accuracies of the most promising DosR encoded antigens in the
diagnosis of TB disease. Only ROC curves for antigens that differentiated between the TB cases and household contacts with AUCs above 0.71
are shown. ROC curves for all other DosR encoded antigens are shown in Additional file 9: Figure S1. AUC = Area under the curve.
Table 2 Abilities of resuscitation promoting factors (rpfs) to discriminate between TB disease and no TB.
Antigen TB cases HHCs P-value AUC Cut-off Sensitivity
(%)
Specificity
(%)
Rv0867c 0.0
(0.0-274.6)
52.2 (0.0-2173.3) < 0.001 0.80 < 1.3 78 (18/23) 85 (17/20)
Rv2389c 0.0
(0.0-209.2)
25.8 (0.0-1056.0) 0.002 0.78 < 0.9 78 (18/23) 80 (16/20)
Rv2450c 0.0
(0.0-209.8)
29.2 (0.0-1123.5) 0.003 0.76 < 10.3 74 (17/23) 80 (16/20)
Rv1009 0.0
(0.0-184.2)
27.2 (0.0-1875.0) 0.001 0.79 < 0.3 78 (13/23) 80 (16/20)
Rv1884c 0.0
(0.0-158.3)
4.0 (0.0-481.1) 0.012 0.72 < 1.3 87 (20/23) 60 (12/20)
Median levels of IFN-g (pg/ml) and ranges (in parenthesis) elicited upon stimulation of whole blood with rpfs and ability to discriminate between pulmonary TB
(in 23 cases) and no TB disease (in 20 HHCs). AUC = Area under the ROC curve
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Figure 3 Receiver operating characteristic curves showing the accuracies of the resuscitation promoting factors in the diagnosis of TB
disease. AUC = Area under the curve.
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Figure 4 Number of inclusions of antigens into the 10 general discriminant analysis models that most accurately predicted the
presence or absence of TB disease. PHA was evaluated in all study participants as a positive control, and appeared in one of the models
because IFN-g data was analyzed in a blinded manner.
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Page 8 of 14use of serological tests for the diagnosis of TB disease
[46].
The DosR regulon of M.tb is upregulated when M.tb
is subjected to conditions that mimic latency including
hypoxia, nutrient starvation, low nitric oxide or low pH
[10,19,47-50]. IFN-g responses elicited by 14 of the
DosR antigens evaluated in this study were significantly
higher in HHCs compared to TB cases, and 8 of these
antigens (Rv2032, Rv2625c, Rv1996, Rv0081, Rv2624c,
Rv2006, Rv2629 and Rv2007c) showed promise as diag-
nostic candidates after ROC analysis, although this pro-
mising accuracy was not confirmed by the validation for
the five antigens re-evaluated. The inclusion of some
DosR regulon encoded antigens into GDA models that
best predicted active TB or no TB disease, along with
ESAT-6/CFP-10fp or rpfs, may suggest that these anti-
gens are useful diagnostic candidates and need further
evaluation in larger studies. The finding that DosR
Table 3 Abilities of antigens to differentiate between TB disease and no TB disease after re-evaluation with the
validation ELISA.
Antigen TB cases HHCs P-value AUC Cut-off Value Sensitivity
(%)
Specificity
(%)
Rv0867c 1.0 (0-43.8) 25.5 (0-257.5) 0.009 0.78 > 29.3 47 (7/15 93 (14/15)
Rv1009 0.6 (0-27.1) 9.8 (0-273.4) 0.012 0.77 < 1.4 53 (8/15) 87 (13/15)
Rv2389c 0.4 (0-29.5) 23.6 (0-297.4) 0.005 0.80 < 0.1 40 (6/15) 93 (14/15)
Rv0081 0.2 (0-400.0) 1.3 (0-97.1) 0.146 0.65 < 0.1 20 (3/15) 93 (14/15)
Rv1996 0.8 (0-33.7) 0 (0-195.4) 0.771 0.53 > 7.6 20 (3/15) 93 (14/15)
Rv2032 0.5 (0-21.0) 1.3 (0-400.0) 0.120 0.67 < 0.1 47 (7/15) 86 (12/14)
Rv2624c 0 (0-3.7) 0 (0-1.7) 0.295 0.61 < 0.1 27 (4/15) 93 (14/15)
Rv2625c 0.3 (0-31.4) 1.3 (0-400.0) 0.262 0.62 < 0.1 47 (7/15) 87 (13/15)
ESAT-6/CFP-10 305 (0-400.0) 308 (0-400.0) 0.712 0.53 > 441.2 33 (5/15) 96 (26/28)
Median levels of IFN-g (pg/ml) and ranges (in parentheses) detected in supernatants from TB cases (n = 15) and household contacts (n = 15) after evaluation
with the Quantiferon TB Gold ELISA are shown. IFN-g values were corrected for the unstimulated control levels and responses > 10 IU/ml (400 pg/ml) were given
a value of 400 pg/ml. AUC = Area under the ROC curve
Table 4 Accuracy of antigens in diagnosing TB disease when used in combinations.
Antigen
combination
Resubstitution Classification Matrix Leave-one-out Cross validation Wilks lambda f P-value
% TB cases % HHCs Total % % TB cases % HHCs
ESAT-6/CFP-10
Rv2624c Rv2389c
86.7
(13/15)
73.3
(11/15)
80.0 73.3
(11/15)
73.3
(11/15)
0.59 18.3 0.0002
ESAT-6/CFP-10
Rv2624c Rv0867c
86.7
(13/15)
80.0
(12/15)
83.3 73.3
(11/15)
80.0
(12/15)
0.60 17.5 0.0002
ESAT-6/CFP-10
Rv2624c Rv1009
73.3
(11/15)
73.3
(11/15)
73.3 66.7 (10/15) 66.7 (10/15) 0.62 16.3 0.0004
Rv2032
Rv2624c Rv0867c
80.0 (12/15) 78.6 (11/14) 79.3 80.0 (12/15) 71.4 (10/14) 0.39 38.7 < 0.0001
Rv2032
Rv2624c
Rv2389c
86.7 (13/15) 78.6 (11/15) 82.7 86.7 (13/15) 64.3
(9/14)
0.39 39.3 < 0.0001
Rv2032
Rv2624c
Rv1009
86.7 (13/15) 71.4 (10/14) 79.3 86.7
(13/15)
64.3
(9/14)
0.41 36.1 < 0.0001
ESAT-6/CFP-10
Rv2032 Rv2389c
80.0 (12/15) 71.4
(10/14)
75.9 80.0
(12/15)
64.3
(9/14)
0.61 15.9 0.0005
ESAT-6/CFP-10
Rv2032 Rv0867c
80.0
(12/15)
78.6
(11/14)
79.3 73.3
(11/15)
71.4
(10/14)
0.62 15.6 0.0005
ESAT-6/CFP-10
Rv2032 Rv1009
73.3 (11/15) 71.4 (10/14) 72.4 73.3
(11/15)
64.3
(9/14)
0.63 14.5 0.0008
ESAT-6/CFP-10
Rv2032 Rv2624c
60.0
(9/15)
64.3 (9/14) 62.1 53.3
(8/15)
64.3
(9/14)
0.67 12.5 0.0015
Abilities of combinations of antigens to discriminate between TB disease and no TB in General Discriminant Analysis models after supernatants were re-evaluated
with the Quantiferon TB Gold ELISA. In each case, effect df = 1, error df = 25
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Page 9 of 14antigens are more frequently recognized in HHCs (many
of whom we would expect to be latently infected and all
of whom have at least been exposed to M.tb) has also
been observed in other studies [13,19-21]. Recognition
of the DosR antigen Rv2628 was associated with cured
tuberculosis and remote infection in a study in Italy
[51]. Moreover, an increased frequency of the response
to Rv2628 at the site of TB disease in patients with
active TB has been found [52].
Like the DosR antigens, the reactivation antigens and
t h er p f sw e r em o r ef r e q u e n t l yr e c o g n i z e di nH H C s ,
with the rpfs being the most discriminatory between the
TB and non-TB cases. Rpfs are growth-promoting pro-
teins and have been shown to resuscitate dormant bac-
teria, as well as enhance the growth of bacteria,
including M.tb in both liquid and solid media [53]. M.tb
rpfs have been shown to be immunogenic in TST-posi-
tive individuals and to elicit strong CD4 and CD8 T
cell-dependent responses in vitro, in long-term latently
infected individuals [21,54]. The more frequent recogni-
tion of rpfs (believed to be predominantly expressed
during the exponential growth phases [53,55]), in
latently infected individuals is consistent with the notion
that M.tb exists in a dormant, non-replicating or only
slowly replicating state in LTBI [56,57]. As has been
suggested previously, the bacteria may indeed still be
replicating but are controlled by the host immune
response in an ‘active infection’ [58]. As suggested by
Commandeur et al. [54], the presence of some of the
rpfs in culture filtrate may imply higher availability and
recognition by immune cells. Furthermore, the existence
of M.tb in different metabolic states in its host during
infection [57] would imply that T cells are exposed
(although perhaps in different amounts) to antigens
from different infection phases in vivo-hence their
recognition in in vitro stimulation assays. This would
also explain the recognition of DosR antigens in TB
patients. Whatever the case, antigens that are recog-
nized in both TB patients and latently infected indivi-
duals are less well suited for discriminating between
different M.tb infection states but could add to the cur-
rently used RD1 antigens in the diagnosis of M.tb infec-
tion provided they are potent cytokine inducers in
short-term culture assays.
To the best of our knowledge, no other study has
investigated such a large number of different M.tb infec-
tion phase-dependent antigens as diagnostic candidates
in a high TB-endemic setting; and little or no informa-
tion is currently available about the diagnostic potential
of most of the antigens investigated in this study. More
studies are therefore needed in different population
groups to verify the findings of this first screening study.
A serious concern in the possible use of new antigens
such as those investigated in this study for diagnostic
purposes is a lack of specificity for M.tb.S o m eo ft h e
DosR antigens evaluated in this study have been shown
to be expressed in BCG vaccine strains [47] but BCG
vaccination was reported not to induce T cell responses
to DosR antigens, likely because BCG fails to establish
long-lived latent infections and therefore may not
express (or under express) these antigens in vivo follow-
ing vaccination [59].
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Figure 5 Number of inclusions of antigens in the 10 most accurate general discriminant analysis combinations that most accurately
predicted the presence or absence of TB disease after supernatants were re-evaluated by the Quantiferon TB Gold ELISA.
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Page 10 of 14Although none of the classical TB antigens were cap-
able of discriminating between active TB and no TB,
ESAT-6/CFP-10fp was included in most of the top GDA
models that best discriminated between the presence
and absence of TB disease. It is known that the mea-
surement of IFN-g elicited by ESAT-6/CFP-10 does not
discriminate between active TB and LTBI. However, it
h a sp r o v e nt ob ea ne x c e l l e n tm a r k e ro fM.tb infection
and this is consistent with the inclusion of ESAT-6/
CFP-10fp into all the best discriminatory models. The
results suggest that evaluating the DosR antigens or
rpfs, which were most predominantly recognized in
HHCs, in combination with ESAT-6/CFP-10 could
enhance our ability to differentiate LTBI from TB dis-
ease in RD1 antigen-positive individuals. When IFN-g
responses against the different antigens were analysed
only amongst participants that responded to ESAT-6/
CFP-10fp, significant p-values were obtained for all the
five rpfs (Rv0867c, Rv2389c, Rv2450c, Rv1009, Rv1884c),
11 DosR encoded antigens (Rv3129, Rv2625c, Rv1996,
Rv2032, Rv3126c, Rv2631, Rv3130c, Rv2624c, Rv2007c,
Rv3131, Rv3127) and two TB reactivation antigens
(Rv1471, Rv3862c). Furthermore, the AUCs for all these
18 antigens in discriminating between TB disease and
no TB in the ESAT-6/CFP-10fp responsive participants
was above 0.70 (data not shown). Because of the
explorative nature of this study, the contributions of the
different antigens in the predictive models will need to
be investigated further in ongoing follow-up studies.
The main limitations of our study include the rela-
tively small sample size, the use of 7-day WBA instead
of overnight assays which would be more suitable for a
diagnostic study, and the unavailability of accurate LTBI
diagnostic data for the HHCs. The HHCs that partici-
pated in this study were recruited from a high TB ende-
mic area [3,60] where it is known that up to 89% of
H H C sm a yb eT S Tp o s i t i v e ,w i t h7 4 %b e i n gQ F Tp o s i -
tive in a previous study [5,13,17]. However the M.tb
infection status of participants recruited into future fol-
low up studies should be better characterized, so as to
e n a b l eam o r ea c c u r a t ee s t i m a t i o no ft h ed i s c r i m i n a t i v e
abilities of the antigens between active TB disease and
LTBI. This could be done by means of IGRAs and
appropriate contact scores based on TB exposure gradi-
ent as has been done previously [5,6,61]. For the major-
ity of the antigens evaluated in this study, no
information was previously available about their immu-
nogenicity in M.tb infected individuals. We therefore
chose to evaluate the antigens using a long-term whole
blood culture assay in order to detect any existing
immune responses to the antigens, including memory
responses. Future evaluation of diagnostic candidates
should be done in larger numbers of participants, in
overnight assays to detect effector cell responses, and
preferably using a prospective study design. Potentially
useful candidates should also be evaluated in children,
immunocompromised individuals, extrapulmonary TB
cases and also in individuals with other lung diseases.
Because of the need for new TB diagnostic tests to be
rapid and less technically demanding, the use of other
platforms such as serodiagnosis and the possibility of
employing cocktails of antigens should be evaluated.
Our data indicates that the two ELISAs employed in
this study might not deliver comparable results as only
three of the eight promising antigens re-evaluated with
the QFT ELISA showed the same promising accuracy
obtained with the “BD ELISA”. The reasons behind this
discrepancy were not investigated further in this study
as these technical issues are beyond the scope of this
screening study that was designed to identify possible
diagnostic antigen candidates. The discrepancies could
however, be due to technical aspects that might be
inherent in the two ELISAs (the “BD ELISA” with an 8-
point 4PL standard curve ranging from 31 pg/ml to
4000 pg/ml versus the QFT ELISA with a 3-point linear
standard curve ranging from 0.25 IU/ml to 4.0 IU/ml).
ELISA assays used in future studies should be carefully
selected, taking into consideration technical aspects
including detection limits, to enable more accurate
detection of a broad range of IFN-g responses. Finally,
multiplex cytokine analysis assays could be used to eval-
uate other biomarkers [1,17,62] in supernatants from
antigens that did or did not elicit IFN-g responses since
the lack of an IFN-g response does not necessarily imply
that the antigen is not recognized by T cells. The possi-
bility of establishing a useful diagnostic signature com-
prising a pattern of host responses to different M.tb
antigens should be investigated.
Conclusions
In conclusion, IFN-g responses to TB rpfs associate with
latency and show promise as TB diagnostic candidates.
The findings of this study are preliminary and require
validation in other studies and in other settings.
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Additional file 1: Table S1. Details of the M.tb well-characterized
antigens evaluated in the study. *Antigen 85 A and B were tested
together in culture, hence assigned the same study code, p = peptide
pool.
Additional file 2: Table S2. Details of the DosR regulon encoded
antigens evaluated in the study.
Additional file 3: Table S3. Description of the TB reactivation antigens
evaluated in the study.
Additional file 4: Table S4. Description of the resuscitation promoting
factors evaluated in the study.
Additional file 5: Table S5. Description of the other M. tb stress
induced proteins evaluated in the study.
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Page 11 of 14Additional file 6: Table S6. Description of the starvation antigens
evaluated in the study.
Additional file 7: Table S7. Sequences of the peptide pools evaluated
in the study.
Additional file 8: Table S8. Median levels of IFN-g (pg/ml) and Inter
quartile range (25th to 75th percentile, in parenthesis) elicited upon
stimulation of whole blood with different M.tb infection phase-
dependent antigens and abilities to discriminate between pulmonary TB
disease (in 23 cases) and no TB disease (in 19-21 household contacts).
AUC = Area under the curve, 95% CI = 95% Confidence interval. The p-
values shown are Mann Whitney U test P values for differences between
the TB cases and HHCs. The cut-off values are for the sensitivity and
specificity for TB disease. Antigens were sorted according to AUC
(highest to lowest) for discriminating between TB disease and no TB
disease.
Additional file 9: Figure S1. Receiver operating characteristic curves
showing the accuracies of all antigens evaluated in the study in
discriminating between TB disease and no TB disease. AUC = Area under
the curve.
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